» Articles » PMID: 35586934

Bactericidal Effect of Cecropin A Fused Endolysin on Drug-Resistant Gram-Negative Pathogens

Overview
Date 2022 May 19
PMID 35586934
Authors
Affiliations
Soon will be listed here.
Abstract

The rapid spread of superbugs leads to the escalation of infectious diseases, which threatens public health. Endolysins derived from bacteriophages are spotlighted as promising alternative antibiotics against multi-drug resistant bacteria. In this study, we isolated and characterized the novel phage PBST08. Bioinformatics analysis of the PBST08 genome revealed putative endolysin ST01 with a lysozyme-like domain. Since the lytic activity of the purified ST01 was minor, probably owing to the outer membrane, which blocks accessibility to peptidoglycan, antimicrobial peptide cecropin A (CecA) was fused to the N-terminus of ST01 to disrupt the outer membrane. The resulting CecA::ST01 has been shown to have increased bactericidal activity against gram-negative pathogens including , , , , and and the most affected target was . In the presence of 0.25 μM CecA::ST01, ATCC 17978 strain was completely killed and CCARM 12026 strain was wiped out by 0.5 μM CecA::ST01, which is a clinical isolate of and resistant to multiple drugs including carbapenem. Moreover, the larvae of could be rescued up to 58% or 49% by the administration of CecA::ST01 upon infection by 17978 or CCARM 12026 strain. Finally, the antibacterial activity of CecA::ST01 was verified using 31 strains of five gram-negative pathogens by evaluation of minimal inhibitory concentration. Thus, the results indicate that a fusion of antimicrobial peptide to endolysin can enhance antibacterial activity and the spectrum of endolysin where multi-drug resistant gram-negative pathogens can be efficiently controlled.

Citing Articles

A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections.

Rahimian M, Jafari-Gharabaghlou D, Mohammadi E, Zarghami N Phage (New Rochelle). 2025; 5(4):203-222.

PMID: 40045937 PMC: 11876824. DOI: 10.1089/phage.2024.0011.


The Unique Capability of Endolysin to Tackle Antibiotic Resistance: Cracking the Barrier.

Sabur A, Khan A, Borphukan B, Razzak A, Salimullah M, Khatun M J Xenobiot. 2025; 15(1).

PMID: 39997362 PMC: 11856723. DOI: 10.3390/jox15010019.


Retrospective analysis of the impact of pathogen spectrum and antibiotic resistance on the treatment efficacy of respiratory tract infections from 2012 to 2022.

Chen Y, Fang S Am J Transl Res. 2025; 17(1):480-488.

PMID: 39959241 PMC: 11826203. DOI: 10.62347/XZCT4326.


The antibacterial activity of a novel highly thermostable endolysin, LysKP213, against Gram-negative pathogens is enhanced when combined with outer membrane permeabilizing agents.

Chu D, Lan J, Liang L, Xia K, Li L, Yang L Front Microbiol. 2024; 15:1454618.

PMID: 39439944 PMC: 11493673. DOI: 10.3389/fmicb.2024.1454618.


Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model.

Lim J, Myung H, Lim D, Song M J Biomed Sci. 2024; 31(1):36.

PMID: 38622637 PMC: 11020296. DOI: 10.1186/s12929-024-01027-4.


References
1.
Saeed S, Mergani A, Aklilu E, Kamaruzzman N . Antimicrobial Peptides: Bringing Solution to the Rising Threats of Antimicrobial Resistance in Livestock. Front Vet Sci. 2022; 9:851052. PMC: 9024325. DOI: 10.3389/fvets.2022.851052. View

2.
Jado I, Lopez R, Garcia E, Fenoll A, Casal J, Garcia P . Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother. 2003; 52(6):967-73. DOI: 10.1093/jac/dkg485. View

3.
Gerstmans H, Rodriguez-Rubio L, Lavigne R, Briers Y . From endolysins to Artilysin®s: novel enzyme-based approaches to kill drug-resistant bacteria. Biochem Soc Trans. 2016; 44(1):123-8. DOI: 10.1042/BST20150192. View

4.
Quevillon E, Silventoinen V, Pillai S, Harte N, Mulder N, Apweiler R . InterProScan: protein domains identifier. Nucleic Acids Res. 2005; 33(Web Server issue):W116-20. PMC: 1160203. DOI: 10.1093/nar/gki442. View

5.
Briers Y, Walmagh M, Van Puyenbroeck V, Cornelissen A, Cenens W, Aertsen A . Engineered endolysin-based "Artilysins" to combat multidrug-resistant gram-negative pathogens. mBio. 2014; 5(4):e01379-14. PMC: 4161244. DOI: 10.1128/mBio.01379-14. View